Ceftobiprole for the treatment of pneumonia
Rev. esp. quimioter
; 32(supl.3): 17-23, sept. 2019. tab, graf
Artigo
em Inglês
| IBECS
| ID: ibc-188974
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Ceftobiprole is a fifth-generation cephalosporin with potent antimicrobial activity against Gram positive and Gram-negative bacteria. It has been approved in major European countries for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Ceftobiprole is currently in a phase 3 clinical program for registration in the U. S. In 2015, it was designated as an infectious disease product qualified for the treatment of lung and skin infections by the FDA. The efficacy of ceftobiprole in pneumonia has been demonstrated in two-phase III clinical trials conducted in patients with CAP and HAP. The recommended dose in the adult with pneumonia is 500 mg every 8 h infused in 2 h; in case of renal failure, the regimen of administration must be adjusted according to the patient's renal function. It is not necessary to adjust the dose according to gender, age, body weight or liver failure. In case of hyperfiltration, an extension to 4 h infusion of the 500mg TID is required
RESUMEN
No disponible
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Infecção Hospitalar
/
Infecções Comunitárias Adquiridas
/
Pneumonia Bacteriana
/
Antibacterianos
Limite:
Humanos
Idioma:
Inglês
Revista:
Rev. esp. quimioter
Ano de publicação:
2019
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Clinic of Barcelona/Spain
/
University of Barcelona/Spain
/
Università Cattolica del Sacro Cuore [Catholic University of the Sacred Heart]/Italy